OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
LON.NLB58

Lonza Group AG

Biotechnology & Medical ResearchVerified

Lonza Group AG has a capital structure that is currently undetermined due to the lack of balance-sheet inputs and no going-concern language in the source documents. Analysts have provided a range of price targets for the company, with a mean of 666.00 CHF and a median of 667.50 CHF, indicating a generally positive outlook from the investment community. The company's profitability and returns are not currently quantifiable due to the absence of detailed financial metrics in the valuation snapshot. However, the mean recommendation of 1.92 suggests that analysts are largely optimistic about Lonza's future performance, with 5 strong-buy and 17 buy ratings. Lonza's segments and geographic exposure are not explicitly detailed in the available data, but the company operates globally, with a focus on the life sciences industry. The lack of detailed segment data limits the ability to assess revenue concentration or geographic risk. The growth trajectory of Lonza Group AG is not quantified in the available data, but the positive analyst sentiment and the absence of dilution risk suggest a stable or potentially growing company. The company's outlook for the current and next fiscal years is not provided, but the low dilution risk indicates that there is no immediate threat to shareholder value from new share issuance. The risk assessment for Lonza Group AG indicates that liquidity risk could not be assessed due to the lack of balance-sheet inputs and no going-concern language in the source documents. The dilution risk is low, and there are no specific risk factors detailed in the available data. The absence of detailed risk factors and the lack of liquidity data suggest that further analysis is needed to fully understand the company's risk profile. Recent events and filings for Lonza Group AG are not detailed in the available data. The company's recent performance and strategic initiatives are not explicitly mentioned, but the positive analyst sentiment and the absence of dilution risk suggest that the company is in a stable position.

30-day price · LON.NLB(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyLonza Group AG
TickerLON.NLB
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. Lonza Group AG is a Swiss multinational company that provides a range of services in the life sciences industry, including the development, manufacturing, and distribution of active pharmaceutical ingredients, biopharmaceuticals, and diagnostic products.

Classification. Lonza Group AG is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Biotechnology & Medical Research industry, with a confidence level of 0.92.

Lonza Group AG has a capital structure that is currently undetermined due to the lack of balance-sheet inputs and no going-concern language in the source documents. Analysts have provided a range of price targets for the company, with a mean of 666.00 CHF and a median of 667.50 CHF, indicating a generally positive outlook from the investment community. The company's profitability and returns are not currently quantifiable due to the absence of detailed financial metrics in the valuation snapshot. However, the mean recommendation of 1.92 suggests that analysts are largely optimistic about Lonza's future performance, with 5 strong-buy and 17 buy ratings. Lonza's segments and geographic exposure are not explicitly detailed in the available data, but the company operates globally, with a focus on the life sciences industry. The lack of detailed segment data limits the ability to assess revenue concentration or geographic risk. The growth trajectory of Lonza Group AG is not quantified in the available data, but the positive analyst sentiment and the absence of dilution risk suggest a stable or potentially growing company. The company's outlook for the current and next fiscal years is not provided, but the low dilution risk indicates that there is no immediate threat to shareholder value from new share issuance. The risk assessment for Lonza Group AG indicates that liquidity risk could not be assessed due to the lack of balance-sheet inputs and no going-concern language in the source documents. The dilution risk is low, and there are no specific risk factors detailed in the available data. The absence of detailed risk factors and the lack of liquidity data suggest that further analysis is needed to fully understand the company's risk profile. Recent events and filings for Lonza Group AG are not detailed in the available data. The company's recent performance and strategic initiatives are not explicitly mentioned, but the positive analyst sentiment and the absence of dilution risk suggest that the company is in a stable position.
Key takeaways
  • Lonza Group AG is a multinational company in the life sciences industry, with a focus on pharmaceuticals and diagnostics.
  • Analysts have a generally positive outlook on Lonza, with a mean price target of 666.00 CHF and a median of 667.50 CHF.
  • The company's capital structure and liquidity risk are currently undetermined due to the lack of balance-sheet inputs.
  • Lonza has a low dilution risk, indicating that there is no immediate threat to shareholder value from new share issuance.
  • The company's profitability and returns are not currently quantifiable, but the positive analyst sentiment suggests a stable or potentially growing company.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCHF
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$5.41B$851.0M$2.94B-$365.0M
FY-3$6.22B$1.54B$1.22B-$282.0M
FY-2$6.72B$880.0M$654.0M-$666.0M
FY-1$5.48B$908.0M$636.0M-$453.0M
FY0$6.53B$1.24B-$275.0M$64.0M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$16.46B$9.75B$628.0M
FY-3$17.36B$10.60B$1.11B
FY-2$16.85B$9.45B$1.20B
FY-1$19.73B$9.33B$685.0M
FY0$17.91B$7.91B$481.0M
PeriodOCFCapExFCFSBC
FY-4$1.22B-$1.34B-$365.0M
FY-3$1.02B-$1.87B-$282.0M
FY-2$1.39B-$1.68B-$666.0M
FY-1$1.27B-$1.42B-$453.0M
FY0$1.16B-$1.38B$64.0M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Healthcare Diagnostics · cohort 170 companies
MetricLON.NLBActivity
Op margin-227.5% medp25 -1250.6% · p75 -3.5%
Net margin-194.5% medp25 -1233.8% · p75 0.8%
Gross margin53.0% medp25 25.9% · p75 75.7%
CapEx / revenue-8.2% medp25 -35.2% · p75 -2.5%
Debt / equity1.2% medp25 0.0% · p75 17.4%
Observations
IR observations
Mean price target666.00 CHF
Median price target667.50 CHF
High price target815.00 CHF
Low price target482.01 CHF
Mean recommendation1.92 (1=strong buy, 5=strong sell)
Strong-buy count5.00
Buy count17.00
Hold count3.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate17.85 CHF
Last actual EPS15.03 CHF
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-01 05:28 UTC#97557dea
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 10:59 UTCJob: 15f9911b